Results 121 to 130 of about 2,212,418 (287)

Integrated Clinical and Proteomic Profiling of CD19 Chimeric Antigen Receptor T Cell Therapy in Progressive Systemic Sclerosis

Arthritis &Rheumatology, EarlyView.
Objective To characterize the clinical, immunologic, and proteomic changes associated with CD19 chimeric antigen receptor T cell therapy in patients with progressive systemic sclerosis (SSc). Methods Patients with progressive SSc received CD19 chimeric antigen receptor (CAR)‐T cell therapy and were observed longitudinally for safety, clinical efficacy,
Chenhan Jia, Wanyi Lin, Zhangyi Zhao, Fenglin Wu, Chaoyu Gu, Yuankai Sun, Zhe Ding, Chang Wei, Xinyu Li, Cuiwei Xie, Peng Xia, Zhen Xia, Xuesong Liu, Shaoying Yang, Chunyan Zhang, Hanlin Yin, Liangjing Lu   +16 more
wiley   +1 more source

Low health literacy and quality of life in patients with systemic arterial hypertension. [PDF]

Dialogues Health, 2022
Cangussú LR, Sartori Alho EA, Silva AL, Fonsêca DV, Lopes JM, Barbosa RHA, Lopes MR.   +6 more
europepmc   +1 more source

PLASMA ENDOTHELIN-1 LEVELS IN PATIENTS WITH SYSTEMIC-SCLEROSIS - INFLUENCE OF PULMONARY OR SYSTEMIC ARTERIAL-HYPERTENSION

, 1995
Objectives - To investigate the behaviour of circulating endothelin-1 (ET-1) in patients affected by systemic sclerosis and to elucidate the relationship between systemic and pulmonary plasma peptide and arterial pressure levels.
CARLESIMO, Marta, U. Bottoni, A. Santucci, MORELLI, Sergio, C. Ferri, R. Baldoncini, VALESINI, Guido, L. Di Francesco, G. Properzi, Carlesimo M., Bottoni U., Valesini G., Properzi G., R Baldoncini, Morelli S., G Properzi, Di Francesco L., M Carlesimo, Baldoncini R., A Santucci, Ferri C., L Di Francesco, C Ferri, U Bottoni, S Morelli, Santucci A.   +25 more
core   +1 more source

Deucravacitinib in Active Psoriatic Arthritis: Efficacy and Safety Up to 52 Weeks From the Randomized, Double‐Blind, Phase 3 POETYK PsA‐2 Trial

Arthritis &Rheumatology, EarlyView.
Objective To assess the efficacy and safety of deucravacitinib, an oral, selective tyrosine kinase 2 inhibitor, in patients with psoriatic arthritis (PsA) who were naive to biologic disease‐modifying antirheumatic drugs or received tumor necrosis factor inhibitors. Methods In the 52‐week, double‐blind, placebo‐controlled, phase 3 Program for Evaluation
Philip J. Mease, Vinod Chandran, April W. Armstrong, Ricardo Blanco, Alexis Ogdie, Evan L. Siegel, Alice B. Gottlieb, Xiaofeng Zeng, Diamant Thaçi, Mitsumasa Kishimoto, Hendrik Schulze‐Koops, Alan Kivitz, Eva Dokoupilová, Akimichi Morita, Eric M. Ruderman, Michael Plewinski, Kejia Wang, Caroline Sardinas, Eleni Vritzali, John Vaile, Atul Deodhar   +20 more
wiley   +1 more source

[Treatment of systemic arterial hypertension].

Archivos de cardiologia de Mexico, 2002
The World Health Organization (WHO) and several other international committees on the study of hypertension define that a patient with blood pressure between 140/90-150/95 mmHg must be treated. In the first stage of hypertension it is possible to modify it with life style changes, but if high blood pressure persists, then drug therapy must be evaluated
Francisca, Arellano, María Elena, Jasso Soto   +1 more
openaire   +1 more source

Cancer in Systemic Sclerosis: Clinical Associations and Prognostic Impact From the EUSTAR Registry

Arthritis &Rheumatology, EarlyView.
Objective Cancer represents a major cause of death in systemic sclerosis (SSc). Established risk factors are limited to specific subsets, particularly early diffuse anti‐RNA polymerase III (POLR3)–positive disease, needing further exploration. Methods We performed a nested case‐control study within the European Scleroderma Trials and Research group ...
Antonio Tonutti, Francesca Motta, Liala Moschetti, Cosimo Bruni, Carina Mihai, Claudia Iannone, Maria Rosa Pellico, Stefano Stano, Stefano Erba, Claudia Barison, Eleonora Pazzi, Andrea Benini, Beatrice Moccaldi, Kurszán Jász Dávid, Ágnes Ágoston‐Szabó, Beatrice Gabrielli, Francesca Nava, Dóra Tari, Francesca Romana Di Ciommo, Yuri Sasaki, Gonçalo Boleto, Radim Bečvář, Alejandro Brigante, Britta Maurer, Massimiliano Limonta, Rahma A. Elziaty, Fabiola Atzeni, Lilian Maria López Núñez, Roberta Foti, Francesco Benvenuti, Brigitte Granel, Elena Rezus, Leila Caillault, Sophie Blaise, Cristiana Sieiro Santos, Fabio Cacciapaglia, Roberto Giacomelli, Rossella De Angelis, Serena Guiducci, Duygu Temiz Karadag, Gabriella Szűcs, Luca Idolazzi, Gábor Kumánovics, Florenzo Iannone, Maurizio Cutolo, Gianluca Moroncini, Valeria Riccieri, Nicoletta Del Papa, Elisabetta Zanatta, Oliver Distler, Masataka Kuwana, Carlo Selmi, Maria De Santis   +52 more
wiley   +1 more source

Challenges faced by patients with dyslipidemia and systemic arterial hypertension in Brazil: a design of the patient journey. [PDF]

BMC Cardiovasc Disord, 2022
Faria-Neto JR, Yarleque C, Vieira LF, Sakane EN, Santos RD.   +4 more
europepmc   +1 more source

Systemic Arterial Hypertension

Journal of the American College of Cardiology, 2021
openaire   +1 more source

2023 ESH Guidelines for the management of arterial hypertension The Task Force for the management of arterial hypertension of the European Society of Hypertension: Endorsed by the International Society of Hypertension (ISH) and the European Renal Association (ERA).

2023 ESH Guidelines for the management of arterial hypertension The Task Force for the management of arterial hypertension of the European Society of Hypertension: Endorsed by the International Society of Hypertension (ISH) and the European Renal ...
Kreutz, Reinhold, Lurbe i Ferrer, Empar, Redon, Josep, Mancia, Giuseppe   +3 more
core   +1 more source

Initial Treatment Strategies and Outcomes Across Hemodynamic Thresholds and Risk Stratification in Incident Systemic Sclerosis–Associated Pulmonary Arterial Hypertension: A EUSTAR Analysis

Arthritis &Rheumatology, EarlyView.
Objective Real‐world initial treatment strategies in systemic sclerosis–associated pulmonary arterial hypertension (SSc‐PAH) remain incompletely described. We aimed to characterize these strategies across hemodynamic thresholds and risk strata and evaluate outcome associations. Methods We analyzed treatment‐naive patients with SSc‐PAH from the European
Hilde Jenssen Bjørkekjær, Cosimo Bruni, Kaspar Broch, Cathrine Brunborg, Patricia E. Carreira, Paolo Airò, Carmen Pilar Simeón‐Aznar, Marie‐Elise Truchetet, Alessandro Giollo, Alexandra Balbir‐Gurman, Mickael Martin, Christopher P. Denton, Armando Gabrielli, Francesco Del Galdo, Madelon C. Vonk, Håvard Fretheim, Helle Bitter, Øyvind Midtvedt, Arne K. Andreassen, Sverre Høie, Yoshiya Tanaka, Gabriela Riemekasten, Ulf Müller‐Ladner, Marco Matucci‐Cerinic, Ivan Castellví, Elise Siegert, Eric Hachulla, Øyvind Molberg, Oliver Distler, Anna‐Maria Hoffmann‐Vold, on behalf of the European Scleroderma Trials and Research (EUSTAR) collaborators, Serena Guiducci, Florenzo Iannone, Simona Rednic, Yannick Allanore, Carlomaurizio Montecucco, Gábor Kumánovics, Michele Iudici, Gianluca Moroncini, Kristofer Andréasson, Luca Idolazzi, Jörg Henes, Johannes Pflugfelder, José António Pereira da Silva, Michael Hughes, Valeria Riccieri, Andra Balanescu, Ana Maria Gheorghiu, Christina Bergmann, Francesco Paolo Cantatore, Ellen De Langhe, Branimir Ani, Carolina de Souza Müller, Kamal Solanki, Edoardo Rosato, Britta Maurer, Lesley Ann Saketkoo, Massimiliano Limonta, Vivien M. Hsu, Lorinda S Chung, Yair Levy, Petros Sfikakis, Susana Oliveira, Masataka Kuwana   +63 more
wiley   +1 more source